IfPA’s Patient Access Policy Blog

Drug Safety Data Underscores Need for Pharmacovigilance

One in every three new drugs triggers side effects discovered only after Food and Drug Administration approval, new data reveals.  And that statistic begs a

Read More

Access Issues Loom Large at Munich Workshop on Biologics and Biosimilars

By Brian Kennedy, Executive Director of the Global Alliance for Patient Access When should patients switch from one medicine to another for non-medical reasons?  How can

Read More

How Balanced Treatment, Innovation & Better Policy Can Help Solve the Opioid Epidemic

“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis.  Yet it presents physicians like

Read More

Clinical Trials Awareness Week Focuses on Policy, Participation

What can the federal government do to raise clinical trials awareness?  Maybe a lot, suggests one organization. May 1-5 marks Clinical Trials Awareness Week, when

Read More

Health Plan Report Cards Reveal High Rejection Rate for Cholesterol Meds

Rejection is never pleasant.  But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.

Read More

Tubing Mix-ups Pose New Dangers for Infants

Robin Rogers was 35 weeks pregnant when she began to suffer from significant vomiting and dehydration. She was admitted to the hospital near her home

Read More

Keeping Asthma Medication within Patients’ Reach

A new bureaucratic obstacle could make it even harder for asthma patients to get the medicine they need. For several years now, high cost-sharing has

Read More

Trials Data Raises Hopes in Cystic Fibrosis Community

Promising clinical trials data has excited patients with cystic fibrosis and their families.  But will access barriers dash their hopes for more and better treatment

Read More

IfPA Offers the Physician’s Perspective on Oncology Value Models

What is good value in terms of cancer treatment?  The question, amid rising cancer care costs, has prompted a surge of oncology value models in

Read More

Summit on Biologics and Biosimilars Tackles Choice, Switching & Patient Access

Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the

Read More
Back to Top